Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01685021 · ClinicalTrials.gov registry record · Phase 2
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)
A Phase 2 study, sponsored by MorphoSys.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT01685021: Clinical Trial Phase 2 study, sponsored by MorphoSys.
NCT01685021 is a Phase 2 study that was terminated before completion, run by MorphoSys. The registered enrollment target is 22 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01685021, a Phase 2 study, was terminated before completion, sponsored by MorphoSys.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is an open-label, multicentre study to characterize the safety and preliminary efficacy of the human anti CD19 antibody MOR00208 in adult subjects with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)
Primary Outcome
ORR= CR (Complete Remission) + PR (Partial Remission) Antitumor activity of MOR00208
Interventions
- DRUG MOR00208 (formerly Xmab5574)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Why NCT01685021 stopped before completion
NCT01685021 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which MOR00208 (formerly Xmab5574) is the first listed.
NCT01685021 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01685021 about?
NCT01685021 is a clinical study titled "Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)". This is an open-label, multicentre study to characterize the safety and preliminary efficacy of the human anti CD19 antibody MOR00208 in adult subjects with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)
What is the current status of trial NCT01685021?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2013-04. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01685021?
The interventions under investigation include: MOR00208 (formerly Xmab5574) (DRUG).
Who is sponsoring clinical trial NCT01685021?
This trial is sponsored by MorphoSys, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01685021's enrollment target sits among peer trials
22 1790th of 2000 higher than 207 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia